Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcomaCancer. 2012 Dec 1;118(23):5888-93
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...
Join the Conversation
Please Login or Join to leave comments.